Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Olezarsen in Hypertriglyceridemia and ASCVD
NCT05610280Phase 3Completed
- Sponsor
- Ionis Pharmaceuticals
- Start
- Nov 2022
- Primary completion
- Aug 2024
- Modality
- Modified DNA Oligonucleotides, Single-strand DNA, Antisense Oligonucleotides (ASOs)
- Countries
- 14
01
Overview
Phase 3, randomised, double-blind trial of olezarsen in hypertriglyceridemia, sponsored by Ionis Pharmaceuticals. Primary endpoint: Fasting Triglycerides at 25 weeks. Started Nov 2022; status: completed.
02
Drugs
olezarsen
03
Conditions
hypertriglyceridemia
Beyond the preview
Go deeper on NCT05610280.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05610280.